RxDoctor Payments Data

Milton Shaw, MD

Internal Medicine · Boerne, TXNPI 1346203007

Payments from drug & device makers

$3,082in general payments, 2019–2025

Across 90 payments — averaging $34.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$867
  • Acadia Pharmaceuticals Inc$572
  • Sunovion Pharmaceuticals Inc.$383
  • Urovant Sciences Inc$351
  • Johnson & Johnson$206
  • Novartis$172
  • plus $531 from 8 others

What the payments were for

  • Food & beverage$3,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,082 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$95,411
Medicare patients
472
Services billed
672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban707$205,799
NuplazidPimavanserin Tartrate51$126,412
AustedoDeutetrabenazine39$84,654
IngrezzaValbenazine Tosylate14$76,360
MyrbetriqMirabegron207$51,955
Maraviroc21$28,168
TradjentaLinagliptin103$26,876
XareltoRivaroxaban91$26,302
Divalproex Sodium435$21,902
NamzaricMemantine Hcl/Donepezil Hcl74$21,674
FanaptIloperidone22$20,704
TrulicityDulaglutide20$18,292
JardianceEmpagliflozin58$18,220
AptivusTipranavir18$17,984
MounjaroTirzepatide21$15,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$572$126,41251 claims
Teva Pharmaceuticals USA, Inc.Austedo$50$84,65439 claims
Neurocrine Biosciences, Inc.Ingrezza$867$76,36014 claims
AbbVieNamzaric, Vraylar, Linzess$12$38,457105 claims
Lilly USA, LLCTrulicity, Mounjaro$87$34,27641 claims
Johnson & JohnsonXarelto$206$26,30291 claims
Sumitomo Pharma America, Inc.Gemtesa$34$14,82260 claims
Avanir Pharmaceuticals, Inc.Nuedexta$165$11,60515 claims
Otsuka America Pharmaceutical, Inc.Rexulti$50$10,09714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →